Patient
SITE009-0040
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE009 (AUS) (Dr. Novak)
consented 2025-10-11
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 9
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-12 (study day 77); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-07-12 (study day 77); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 63); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-06-18 (study day 53); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-06-11 (study day 46); relationship: not assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-25 (study day 29); relationship: not assessed; serious criteria: hospitalization
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-05-19 (study day 23); relationship: NOT RELATED
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-14 (study day 18); relationship: NOT RELATED
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-04-30 (study day 4); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.